{"data":{"id":1595,"lang":"en","title":"Pfizer Q1 2026 Revenue Beats at $14.45 Billion as Metsera Monthly Obesity Drug PF-3944 Hits 12.3% Weight Loss in Phase IIb","summary":"Pfizer beat Q1 2026 expectations with $14.45B revenue (+5%) and $0.75 EPS as monthly obesity drug PF-3944 hit 12.3% weight loss in Phase IIb VESPER-3.","category":"business","category_label":"Business","published_at":"2026-05-05T22:03:10Z","updated_at":"2026-05-05T22:03:10Z","url":"https://techtools.cz/tools/news/article/1595-pfizer-q1-2026-revenue-beats-at-14-45-billion-as-metsera-monthly-obesity-drug","api_url":"https://techtools.cz/news-api/v1/articles/1595?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1595.md?lang=en","image_url":"https://i-invdn-com.investing.com/news/LYNXNPEC0Q0MJ_L.jpg","word_count":151,"reading_time_minutes":1,"sources":[{"url":"https://www.cnbc.com/2026/05/05/pfizer-pfe-earnings-q1-2026.html","domain":"cnbc.com"},{"url":"https://www.fool.com/earnings/call-transcripts/2026/05/05/pfizer-pfe-q1-2026-earnings-transcript/","domain":"fool.com"},{"url":"https://www.investing.com/news/company-news/pfizer-q1-2026-slides-beats-estimates-on-acquired-assets-strength-93CH-4660178","domain":"investing.com"}],"translation":{"lang":"cs","id":1668,"title":"Tržby Pfizeru v 1. čtvrtletí 2026 překonaly odhady na 14,45 miliardy dolarů, měsíční lék na obezitu PF-3944 z Metsery dosáhl 12,3% úbytku hmotnosti","url":"https://techtools.cz/tools/news/clanek/1668-trzby-pfizeru-v-1-ctvrtleti-2026-prekonaly-odhady-na-14-45-miliardy-dolaru","api_url":"https://techtools.cz/news-api/v1/articles/1668?lang=cs"},"content":"Pfizer reported first-quarter 2026 revenue of $14.45 billion, up 5% year-over-year, with adjusted earnings of $0.75 per share beating the $0.72 consensus. Launched and acquired products generated $3.1 billion with 22% operational growth as Eliquis jumped 13% to $2.17 billion, while the COVID franchise collapsed — vaccine revenue fell 59% to $232 million and Paxlovid dropped 62% to $186 million.\n\nThe Metsera-derived obesity drug PF-3944 (formerly MET-097i) delivered 12.3% weight loss at week 28 in the Phase IIb VESPER-3 trial on monthly dosing, positioning Pfizer to challenge Novo Nordisk and Eli Lilly with ultra-long-acting peptides. Management said Pfizer plans to launch 10 Phase III studies this year and is targeting first Metsera approval in 2028, with broader market presence by 2029.\n\nPfizer reaffirmed full-year guidance of $59.5–62.5 billion in revenue and $2.80–3.00 adjusted EPS, returned $2.4 billion to shareholders via dividends, and noted roughly $7 billion in business-development capacity remains."}}